- Home
- QS vs AXSM Comparison
QS vs AXSM Comparison
Compare QS & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QS | AXSM |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.5B | 8.6B |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | QS | AXSM |
|---|---|---|
| Price | $7.16 | $183.07 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 7 | 17 |
| Target Price | $8.40 | ★ $211.12 |
| AVG Volume (30 Days) | ★ 9.3M | 532.2K |
| Earning Date | 04-22-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 19.15 | ★ 38.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $57.24 |
| Revenue Next Year | $1,827.70 | $55.88 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.77 | $96.09 |
| 52 Week High | $19.07 | $191.50 |
Technical Indicators
Market Signals| Indicator | QS | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 58.24 | 58.71 |
| Support Level | $6.43 | $178.00 |
| Resistance Level | $9.59 | $184.40 |
| Average True Range (ATR) | 0.35 | 5.41 |
| MACD | 0.13 | 1.05 |
| Stochastic Oscillator | 79.38 | 62.52 |
Price Performance
Historical ComparisonAbout QS QuantumScape Corporation
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles and other applications. The company's solid-state lithium-metal battery technology is designed to offer greater energy density, faster charging, and enhanced safety. Its battery cells have none of the host materials used in conventional anodes.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.